Терапевтический архив (Jul 2010)

Transplantation of the bone marrow from a HLA-compatible unrelated donor after immunoablative conditioning in children with acquired aplastic anemia unresponsive to combined immunosuppressive therapy: Preliminary results

  • G A Novichkova,
  • M A Maschan,
  • I P Shipitsyna,
  • Yu V Skvortsova,
  • M I Persiantseva,
  • L L Lebedeva,
  • V O Bobrynina,
  • D D Baidildina,
  • O V Goronkova,
  • G G Solopova,
  • L A Khachatryan,
  • U N Petrova,
  • E V Suntsova,
  • I I Kalinina,
  • V V Sinitsyna,
  • E V Skorobogatova,
  • D N Balashov,
  • Z M Dyshlevaya,
  • L N Shelikhova,
  • E E Kurnikova,
  • P E Trakhtman,
  • A A Maschan

Journal volume & issue
Vol. 82, no. 7
pp. 41 – 47

Abstract

Read online

Aim. To analyze the efficiency of transplantation of the bone marrow from a HLA-compatible unrelated donor and continued immunosuppressive therapy (IST) in children with aplastic anemia (AA) unresponsive to 2 courses of IST. Subjects and methods. The study enrolled 14 children aged 2-16 years (median 9 years). A control group comprised 26 patients in whom IST was continued. The median interval between the diagnosis of AA and transplantation was 26 months (9-156 months). The conditioning regimen consisted of thoracoabdominal irradiation in a dose of 2 Gy, fludarabin (Flu) 100-150 mg/m2, cyclophosphamide (Cy) 100-200 mg/kg, antithymocyte globulin (ATG) in 11 patients and Flu, Cy, and ATG in 3. A graft-versus-host reaction was prevented with mycophenolate mefetil in all the patients, tacrolimus in 11, and cyclosporin A in 3. Donors were compatible for high-resolution typing of 10/10 and 9/10 alleles in 8 and 6 patients, respectively; the source of a transplant was bone marrow in 13 patients and granulocyte colony-stimulating factor-mobilized peripheral blood precursors in one case. Results. Thirteen patients achieved primary engraftment after single transplantation; one patient did after repeat transplantation. Grades I to II graft-versus-host reaction (GVHR) developed in 9 patients; postengraftment life-threatening infections in 3, extensive chronic GVHR in 2, circumscribed GVHR in 7. All fourteen hemopoietic cell transplant recipients followed for a median 17.5 months (range 1-71 months) were survivors. Conclusion. The likelihood of good survival after unrelated transplantations in AA is much higher than that after continued IST: 100% versus 15±11%.

Keywords